# US 2022/0025460 A1 · Method and kit for determining neuromuscular disease in subject

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0025460 A1
- Document ID: US20220025460A1
- Status: Published application
- Kind: A1
- Application number: 16/934,799
- Filed: 2020-07-21
- Published: 2022-01-27
- Earliest claimed: 2020-07-21
- Assignees: The University of Tokyo; OriCiro Genomics, Inc.
- Applicants: The University of Tokyo; OriCiro Genomics, Inc.
- Inventors: Shoji TSUJI; Hiroyuki ISHIURA; Masayuki SU'ETSUGU
- Web page: https://patentgrep.com/patent/US20220025460A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

A method for determining a neuromuscular disease accompanied with a repeat expansion of CGG in a nucleic acid in a subject comprising: obtaining a nucleic acid fragment having a repeat expansion of CGG or a complementary sequence thereof from a nucleic acid sample from the subject, circularizing the nucleic acid fragment with an origin of chromosome (oriC) cassette to form a circular nucleic acid, amplifying the circular nucleic acid to produce a plurality of circular nucleic acids, and detecting the repeat expansion of CGG or the complementary sequence thereof.

## Claims

### Claim 1

A method for determining a neuromuscular disease accompanied with a repeat expansion of CGG in a nucleic acid in a subject comprising:
obtaining a nucleic acid fragment having a repeat expansion of CGG or a complementary sequence thereof from a nucleic acid sample from the subject,
circularizing the nucleic acid fragment with an origin of chromosome (oriC) cassette to form a circular nucleic acid,
amplifying the circular nucleic acid to produce a plurality of circular nucleic acids, and
detecting the repeat expansion of CGG or the complementary sequence thereof.

### Claim 2 (depends on 1)

The method of claim 1 further comprising digesting the amplified circular nucleic acids to obtain amplified nucleic acid fragments, wherein each of the amplified nucleic acid fragments has the repeat expansion of CGG or the complementary sequence thereof.

### Claim 3 (depends on 1)

The method of claim 1, wherein 5′ region of the oriC cassette is complementary to 5′ region of the nucleic acid fragment and 3′ region of the oriC cassette is complementary to 3′ region of the nucleic acid fragment.

### Claim 4 (depends on 1)

The method of claim 1, wherein 5′ region of the oriC cassette is complementary to 3′ region of the nucleic acid fragment and 3′ region of the oriC cassette is complementary to 5′ region of the nucleic acid fragment.

### Claim 5 (depends on 1)

The method of claim 1, wherein the repeat expansion of CGG or the complementary sequence thereof locates between 5′ region and 3′ region of the nucleic acid fragment.

### Claim 6 (depends on 1)

The method of claim 1, wherein 5′ region and 3′ region of the nucleic acid fragment are loci specific to the neuromuscular disease.

### Claim 7 (depends on 1)

The method of claim 1, wherein the nucleic acid fragment is obtained by using a restriction enzyme or a gene editing protein.

### Claim 8 (depends on 1)

The method of claim 1, wherein the neuromuscular disease is selected from the group consisting of neuronal intranuclear inclusion disease, oculopharyngodistal myopathy, and oculopharyngeal myopathy with leukoencephalopathy.

### Claim 9 (depends on 1)

The method of claim 1, wherein the nucleic acid sample is a chromosome DNA.

### Claim 10 (depends on 1)

The method of claim 1, wherein the repeat expansion of CGG is in a gene from the subject.

### Claim 11 (depends on 10)

The method of claim 10,
wherein the neuromuscular disease is neuronal intranuclear inclusion disease, and
wherein the repeat expansion of CGG is in NBPF19/NOTCH2NLC gene.

### Claim 12 (depends on 11)

The method of claim 11, wherein the repeat expansion is greater than 80 repeats.

### Claim 13 (depends on 10)

The method of claim 10,
wherein the neuromuscular disease is oculopharyngodistal myopathy, and
wherein the repeat expansion of CGG is in 5′ untranslated region of LRP12 gene.

### Claim 14 (depends on 13)

The method of claim 13, wherein the repeat expansion is greater than 77 repeats.

### Claim 15 (depends on 10)

The method of claim 10,
wherein the neuromuscular disease is oculopharyngeal myopathy with leukoencephalopathy, and
wherein the repeat expansion of CGG is in LOC642361/NUTM2B-AS1 gene.

### Claim 16 (depends on 15)

The method of claim 15, wherein the repeat expansion is greater than the range in healthy individuals, and wherein the range in healthy individuals is 6 to 14 repeat units.

### Claim 17

A kit for determining a neuromuscular disease accompanied with a repeat expansion of CGG in a nucleic acid in a subject comprising:
a fragmentation reagent configured to obtain a nucleic acid fragment having a repeat expansion of CGG or a complementary sequence thereof from a nucleic acid sample from the subject,
a circularizing reagent configured to circularize the nucleic acid fragment with an origin of chromosome (oriC) cassette to form a circular nucleic acid, and
an amplifying reagent configured to amplify the circular nucleic acid to produce a plurality of circular nucleic acids.

### Claim 18 (depends on 17)

The kit of claim 17 further comprising a digesting reagent to digest the amplified circular nucleic acids to obtain amplified nucleic acid fragments, wherein each of the amplified nucleic acid fragments has the repeat expansion of CGG or the complementary sequence thereof.

### Claim 19 (depends on 17)

The kit of claim 17, wherein 5′ region of the oriC cassette is complementary to 5′ region of the nucleic acid fragment and 3′ region of the oriC cassette is complementary to 3′ region of the nucleic acid fragment.

### Claim 20 (depends on 17)

The kit of claim 17, wherein 5′ region of the oriC cassette is complementary to 3′ region of the nucleic acid fragment and 3′ region of the oriC cassette is complementary to 5′ region of the nucleic acid fragment.

### Claim 21 (depends on 17)

The kit of claim 17, wherein the repeat expansion of CGG or the complementary sequence thereof locates between 5′ region and 3′ region of the nucleic acid fragment.

### Claim 22 (depends on 17)

The kit of claim 17, wherein 5′ region and 3′ region of the nucleic acid fragment are loci specific to the neuromuscular disease.

### Claim 23 (depends on 17)

The kit of claim 17, wherein the fragmentation reagent contains a restriction enzyme or a gene editing protein.

### Claim 24 (depends on 17)

The kit of claim 17, wherein the neuromuscular disease is selected from the group consisting of neuronal intranuclear inclusion disease, oculopharyngodistal myopathy, and oculopharyngeal myopathy with leukoencephalopathy.

### Claim 25 (depends on 17)

The kit of claim 17, wherein the nucleic acid sample is a chromosome DNA.

### Claim 26 (depends on 17)

The kit of claims 17, wherein the repeat expansion of CGG is in a gene from the subject.

### Claim 27 (depends on 26)

The kit of claim 26,
wherein the neuromuscular disease is neuronal intranuclear inclusion disease, and
wherein the repeat expansion of CGG is in NBPF19/NOTCH2NLC gene.

### Claim 28 (depends on 27)

The kit of claim 27 wherein the repeat expansion is greater than 80 repeats.

### Claim 29 (depends on 26)

The kit of claim 26,
wherein the neuromuscular disease is oculopharyngodistal myopathy, and
wherein the repeat expansion of CGG is in 5′ untranslated region of LRP12 gene.

### Claim 30 (depends on 29)

The kit of claim 29, wherein the repeat expansion is greater than 77 repeats.

### Claim 31 (depends on 26)

The kit of claim 26,
wherein the neuromuscular disease is oculopharyngeal myopathy with leukoencephalopathy, and
wherein the repeat expansion of CGG is in LOC642361/NUTM2B-AS1 gene.

### Claim 32 (depends on 31)

The kit of claim 31, wherein the repeat expansion is greater than the range in healthy individuals, and wherein the range in healthy individuals is 6 to 14 repeat units.

### Claim 33

A method for detecting a repeat expansion of CGG in a nucleic acid comprising:
obtaining a nucleic acid fragment having a repeat expansion of CGG or a complementary sequence thereof,
circularizing the nucleic acid fragment with an origin of chromosome (oriC) cassette to form a circular nucleic acid,
amplifying the circular nucleic acid to produce a plurality of circular nucleic acids, and
detecting the repeat expansion of CGG or the complementary sequence thereof.

### Claim 34 (depends on 33)

The method of claim 33 further comprising digesting the amplified circular nucleic acids to obtain amplified nucleic acid fragments, wherein each of the amplified nucleic acid fragments has the repeat expansion of CGG or the complementary sequence thereof.

### Claim 35 (depends on 33)

The method of claim 33, wherein 5′ region of the oriC cassette is complementary to 5′ region of the nucleic acid fragment and 3′ region of the oriC cassette is complementary to 3′ region of the nucleic acid fragment.

### Claim 36 (depends on 33)

The method of claim 33, wherein 5′ region of the oriC cassette is complementary to 3′ region of the nucleic acid fragment and 3′ region of the oriC cassette is complementary to 5′ region of the nucleic acid fragment.

### Claim 37 (depends on 33)

The method of claim 33, wherein the repeat expansion of CGG or the complementary sequence thereof locates between 5′ region and 3′ region of the nucleic acid fragment.

### Claim 38 (depends on 33)

The method of claim 33, wherein the nucleic acid fragment is obtained by using a restriction enzyme or a gene editing protein.

### Claim 39 (depends on 33)

The method of claim 33, wherein the nucleic acid fragment is obtained from a chromosome DNA.

### Claim 40 (depends on 33)

The method of claim 33, wherein the repeat expansion of CGG is in a gene.

### Claim 41

A kit for detecting a repeat expansion of CGG in a nucleic acid comprising:
a fragmentation reagent configured to obtain a nucleic acid fragment having a repeat expansion of CGG or a complementary sequence thereof from a nucleic acid sample,
a circularizing reagent configured to circularize the nucleic acid fragment with an origin of chromosome (oriC) cassette to form a circular nucleic acid, and
an amplifying reagent configured to amplify the circular nucleic acid to produce a plurality of circular nucleic acids.

### Claim 42 (depends on 41)

The kit of claim 41 further comprising a digesting reagent to digest the amplified circular nucleic acids to obtain amplified nucleic acid fragments, wherein each of the amplified nucleic acid fragments has the repeat expansion of CGG or the complementary sequence thereof.

### Claim 43 (depends on 41)

The kit of claim 41 , wherein 5′ region of the oriC cassette is complementary to 5′ region of the nucleic acid fragment and 3′ region of the oriC cassette is complementary to 3′ region of the nucleic acid fragment.

### Claim 44 (depends on 41)

The kit of claim 41, wherein 5′ region of the oriC cassette is complementary to 3′ region of the nucleic acid fragment and 3′ region of the oriC cassette is complementary to 5′ region of the nucleic acid fragment.

### Claim 44 (depends on 41)

The kit of claim 41, wherein the repeat expansion of CGG or the complementary sequence thereof locates between 5′ region and 3′ region of the nucleic acid fragment.

### Claim 46 (depends on 41)

The kit of claim 41, wherein the fragmentation reagent contains a restriction enzyme or a gene editing protein.

### Claim 47 (depends on 41)

The kit of claim 41, wherein the nucleic acid sample is a chromosome DNA.

### Claim 48 (depends on 41)

The kit of claims 41, wherein the repeat expansion of CGG is in a gene.
